MRNA-COVID19 Vaccination Can Be Considered Safe and Tolerable for Frail Patients.

ABSTRACT:

Background

Frail patients are considered at relevant risk of complications due to coronavirus disease 2019 (COVID-19) infection and, for this reason, are prioritized candidates for vaccination. As these patients were originally not included in the registration trials, fear related to vaccine adverse events and disease worsening was one of the reasons for vaccine hesitancy. Herein, we report the safety profile of the prospective, multicenter, national VAX4FRAIL study (NCT04848493) to evaluate vaccines in a large trans-disease cohort of patients with solid or hematological malignancies and neurological and rheumatological diseases.

Methods

Between March 3 and September 2, 2021, 566 patients were evaluable for safety endpoint: 105 received the mRNA-1273 vaccine and 461 the BNT1

SUBMITTER: Lupo-Stanghellini MT 

PROVIDER: S-EPMC8969577 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature